OMZ powder for injection
Ferron Par Pharmaceuticals
Ingredients in every vial
| Omeprazole | 40 mg |
Each package contains
1 vial of 40 mg
Dosage form
 |
Powder for injection |
Dosage formPowder for injection
Flavour
None
W.H.O. classification
A02A
A02A
A.T.C. Level 1
Anatomical Main group
A - Alimentary tract and metabolism
A02A
A.T.C. Level 2
Therapeutic subgroup
A02 - Drugs for Acid Related Disorders
A02A
A.T.C. Level 3
Pharmacological subgroup
A02A - Antacids
Available in
 |
Indonesia |
Warnings
Alcohol
CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.
Pregnancy
CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.
Lactation
CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.
Indication
Alternative therapy for the following conditions which cannot be treated effectively with oral medication:
Duodenal ulcer
Gastric ulcer
Reflux Esophagitis
Zollinger-Ellison syndrome
Duodenal ulcer
Gastric ulcer
Reflux Esophagitis
Zollinger-Ellison syndrome
Dosage
18 YEARS OLD AND ABOVE
Omeprazole intravenous should only be used where oral medication is inappropriate, e.g. in severely ill patients. Dose 40 mg once daily.
For the treatment of Zollinger-Ellison syndrome, dosage must be adjusted according to the individual response.
Dilute OMZ® injection with 10 ml WFI, do not use another solvent. Inject over a period of not less than 2.5 minutes. Inject at a rate no greater than 4 ml/min.
UP TO 18 YEARS
There is no experience with omeprazole injection in children.
Dilute OMZ® injection with 10 ml WFI, do not use another solvent. Inject over a period of not less than 2.5 minutes. Inject at a rate no greater than 4 ml/min.
PATIENTS WITH SEVERE RENAL IMPAIRMENT
No dosage adjustment of OMZ® injection is necessary.
PATIENTS WITH SEVERE HEPATIC IMPAIRMENT
No dosage adjustment of OMZ® injection is necessary.
ELDERLY PATIENTS
No dosage adjustment of OMZ® injection is necessary.
Omeprazole intravenous should only be used where oral medication is inappropriate, e.g. in severely ill patients. Dose 40 mg once daily.
For the treatment of Zollinger-Ellison syndrome, dosage must be adjusted according to the individual response.
Dilute OMZ® injection with 10 ml WFI, do not use another solvent. Inject over a period of not less than 2.5 minutes. Inject at a rate no greater than 4 ml/min.
UP TO 18 YEARS
There is no experience with omeprazole injection in children.
Dilute OMZ® injection with 10 ml WFI, do not use another solvent. Inject over a period of not less than 2.5 minutes. Inject at a rate no greater than 4 ml/min.
PATIENTS WITH SEVERE RENAL IMPAIRMENT
No dosage adjustment of OMZ® injection is necessary.
PATIENTS WITH SEVERE HEPATIC IMPAIRMENT
No dosage adjustment of OMZ® injection is necessary.
ELDERLY PATIENTS
No dosage adjustment of OMZ® injection is necessary.